Outset Medical (NASDAQ:OM) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Outset Medical (NASDAQ:OM - Free Report) from a sell rating to a hold rating in a research report report published on Saturday.

OM has been the topic of a number of other reports. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $21.00 price objective (up from $14.00) on shares of Outset Medical in a report on Wednesday, May 21st. Scotiabank upgraded Outset Medical to a "strong-buy" rating in a research note on Thursday, May 15th. Finally, Stifel Nicolaus set a $15.00 price objective on Outset Medical in a research note on Friday, March 21st.

Outset Medical Stock Performance

OM stock traded down $0.59 during trading on Friday, reaching $20.65. 331,245 shares of the stock were exchanged, compared to its average volume of 115,410. Outset Medical has a twelve month low of $5.85 and a twelve month high of $72.60. The company has a market capitalization of $365.96 million, a P/E ratio of -8.33 and a beta of 2.15. The stock has a 50 day simple moving average of $14.57 and a 200-day simple moving average of $13.75. The company has a current ratio of 6.49, a quick ratio of 5.04 and a debt-to-equity ratio of 4.12.

Outset Medical (NASDAQ:OM - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($3.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($2.69). Outset Medical had a negative return on equity of 175.64% and a negative net margin of 112.57%. The firm had revenue of $29.75 million for the quarter, compared to analyst estimates of $27.81 million. As a group, sell-side analysts anticipate that Outset Medical will post -1.99 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Woodline Partners LP acquired a new position in Outset Medical during the 1st quarter worth $14,663,000. Parkman Healthcare Partners LLC acquired a new position in Outset Medical during the 1st quarter worth $2,556,000. Alyeska Investment Group L.P. bought a new position in Outset Medical in the first quarter valued at about $18,836,000. Durable Capital Partners LP bought a new position in Outset Medical in the first quarter valued at about $19,247,000. Finally, T. Rowe Price Investment Management Inc. bought a new position in Outset Medical in the first quarter valued at about $17,730,000.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.